CLINICAL TRIALS PROFILE FOR THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER

All Clinical Trials for Theophylline 0.08% And Dextrose 5% In Plastic Container

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000575 ↗	Childhood Asthma Management Program (CAMP) Phases I (Trial), II (CAMPCS), III (CAMPCS/2), and IV (CAMPCS/3)	Completed	CAMP Steering Committee	Phase 3	1991-09-01	The purpose of this study is to evaluate the long term effects of anti-inflammatory therapy compared to bronchodilator therapy on the course of asthma, particularly on lung function and bronchial hyperresponsiveness, and on physical and psychosocial growth and development.
NCT00000575 ↗	Childhood Asthma Management Program (CAMP) Phases I (Trial), II (CAMPCS), III (CAMPCS/2), and IV (CAMPCS/3)	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	1991-09-01	The purpose of this study is to evaluate the long term effects of anti-inflammatory therapy compared to bronchodilator therapy on the course of asthma, particularly on lung function and bronchial hyperresponsiveness, and on physical and psychosocial growth and development.
NCT00000575 ↗	Childhood Asthma Management Program (CAMP) Phases I (Trial), II (CAMPCS), III (CAMPCS/2), and IV (CAMPCS/3)	Completed	Johns Hopkins Bloomberg School of Public Health	Phase 3	1991-09-01	The purpose of this study is to evaluate the long term effects of anti-inflammatory therapy compared to bronchodilator therapy on the course of asthma, particularly on lung function and bronchial hyperresponsiveness, and on physical and psychosocial growth and development.
NCT00000577 ↗	Asthma Clinical Research Network (ACRN)	Withdrawn	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	1993-09-01	This study will establish a network of interactive asthma clinical research groups to evaluate current therapies, new therapies, and management strategies for adult asthma.
NCT00000577 ↗	Asthma Clinical Research Network (ACRN)	Withdrawn	Milton S. Hershey Medical Center	Phase 3	1993-09-01	This study will establish a network of interactive asthma clinical research groups to evaluate current therapies, new therapies, and management strategies for adult asthma.
NCT00000578 ↗	NHLBI/NICHD Collaborative Studies of Asthma in Pregnancy	Completed	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 3	1994-04-01	To conduct a collaborative program of research on asthma and pregnancy consisting of two studies: the Asthma in Pregnancy Study (APS) was an observational study to evaluate relationships between asthma severity and treatment programs and perinatal outcome, and the Asthma Therapy in Pregnancy Trial (ATPT) was a randomized clinical trial of inhaled beclomethasone versus theophylline in the treatment of moderate asthma during pregnancy. Both studies were conducted in the Maternal-Fetal Medicine Unit (MFMU) Network, an ongoing group of participating obstetric centers supported by the National Institute of Child Health and Human Development. Studies were co-funded by the NHLBI.
NCT00000578 ↗	NHLBI/NICHD Collaborative Studies of Asthma in Pregnancy	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	1994-04-01	To conduct a collaborative program of research on asthma and pregnancy consisting of two studies: the Asthma in Pregnancy Study (APS) was an observational study to evaluate relationships between asthma severity and treatment programs and perinatal outcome, and the Asthma Therapy in Pregnancy Trial (ATPT) was a randomized clinical trial of inhaled beclomethasone versus theophylline in the treatment of moderate asthma during pregnancy. Both studies were conducted in the Maternal-Fetal Medicine Unit (MFMU) Network, an ongoing group of participating obstetric centers supported by the National Institute of Child Health and Human Development. Studies were co-funded by the NHLBI.

Clinical Trial Conditions for Theophylline 0.08% And Dextrose 5% In Plastic Container

Condition Name

Condition Name for Theophylline 0.08% And Dextrose 5% In Plastic Container
Intervention	Trials
Asthma	22
Chronic Obstructive Pulmonary Disease	9
COPD	8
Lung Diseases	6

Condition MeSH

Condition MeSH for Theophylline 0.08% And Dextrose 5% In Plastic Container
Intervention	Trials
Asthma	21
Lung Diseases	19
Pulmonary Disease, Chronic Obstructive	18
Lung Diseases, Obstructive	14

Clinical Trial Locations for Theophylline 0.08% And Dextrose 5% In Plastic Container

Trials by Country

Trials by Country for Theophylline 0.08% And Dextrose 5% In Plastic Container
Location	Trials
United States	143
China	26
Japan	19
Canada	13
United Kingdom	12

Trials by US State

Trials by US State for Theophylline 0.08% And Dextrose 5% In Plastic Container
Location	Trials
California	13
Missouri	11
Colorado	11
Texas	10
Tennessee	8

Clinical Trial Progress for Theophylline 0.08% And Dextrose 5% In Plastic Container

Clinical Trial Phase

Clinical Trial Phase for Theophylline 0.08% And Dextrose 5% In Plastic Container
Clinical Trial Phase	Trials
PHASE4	1
PHASE3	2
PHASE2	3

Clinical Trial Status

Clinical Trial Status for Theophylline 0.08% And Dextrose 5% In Plastic Container
Clinical Trial Phase	Trials
Completed	72
Unknown status	14
Recruiting	11

Clinical Trial Sponsors for Theophylline 0.08% And Dextrose 5% In Plastic Container

Sponsor Name

Sponsor Name for Theophylline 0.08% And Dextrose 5% In Plastic Container
Sponsor	Trials
National Heart, Lung, and Blood Institute (NHLBI)	10
Washington University School of Medicine	6
Boehringer Ingelheim	4

Sponsor Type

Sponsor Type for Theophylline 0.08% And Dextrose 5% In Plastic Container
Sponsor	Trials
Other	135
Industry	33
NIH	13

Theophylline 0.08% And Dextrose 5% In Plastic Container Market Analysis and Financial Projection

Last updated: April 28, 2026

Theophylline 0.08% + Dextrose 5% in Plastic Container: Clinical, Market, and Projection

What is the product and what clinical evidence supports its use?

Product definition (formulation)

• Active(s): Theophylline 0.08% (w/v)
• Excipient/solvent system: Dextrose 5% (w/v)
• Dosage form: Infusion solution
• Container: Plastic

Clinical trial status No complete, verifiable clinical trial record set is available in the public domain from the supplied prompt for this exact formulation and container configuration (theophylline 0.08% in dextrose 5% in a plastic container). Without an attributable clinical record (trial registry entry, publication, or regulatory assessment tied to this exact concentration and vehicle), a trials update cannot be produced without introducing unsupported facts.

What can be stated from the drug class (non-trial specific) Theophylline is a methylxanthine bronchodilator used in obstructive airway disease management. Dextrose 5% is commonly used as an IV carrier/vehicle and affects osmolarity and solute context for infusion. This does not substitute for trial-level update. No formulation-specific efficacy, dose-response, safety, or comparative data can be asserted here.

---

What is the market structure for theophylline IV infusion products?

Market drivers

• Demand is driven by acute care utilization where IV methylxanthines may be used when inhaled therapy is inadequate or when clinicians seek IV bronchodilation options.
• Purchase behavior is influenced by hospital pharmacy formularies, supply reliability, and container format (plastic vs glass).
• Competitive positioning typically occurs at the level of IV product availability and unit economics rather than claim differentiation, since the molecule is generic and formulations often converge around standard IV vehicles (commonly dextrose or saline).

Key competitive set (how the market typically competes) For theophylline injection/infusion, the competitive set usually includes:

• Other theophylline IV concentrations and diluents (dextrose-based and saline-based)
• Alternative IV bronchodilators (device and guideline driven use patterns)
• Off-formulary or off-label substitution depending on local practice

What cannot be quantified from the prompt A formulation-level market sizing exercise for “theophylline 0.08% in dextrose 5% in plastic container” requires SKU-level identifiers (NDC, strength/pack configuration, GTIN) and source datasets (IQVIA, regulatory submissions, wholesaler transaction feeds, or national reimbursement claims). None are provided in the prompt, so a defensible market number or share breakdown cannot be generated.

---

How should investors project demand and pricing for this exact formulation?

A credible projection depends on five inputs that are not present in the prompt:

1. SKU-level sales baseline (recent annual unit and value)
2. Country scope (US, EU5, specific regions)
3. Formulary coverage (hospital segments)
4. Regulatory stability (availability, recalls, shortages)
5. Price constraints (tendering, reimbursement, and import dynamics)

Without those, any numerical forecast would be invented rather than analyzed. Therefore, no numeric market projection is provided.

What can still be done in a decision-useful way is to provide a projection framework that maps the exact levers that determine volume and pricing for generic IV infusion SKUs in hospitals:

Volume levers

• Acute respiratory seasonality (winter peaks)
• ICU and ED throughput (IV bronchodilator usage)
• Guideline practice patterns for IV methylxanthine use vs alternative bronchodilators
• Stock-out risk for theophylline IV SKUs (affects reorder frequency and substitution)

Pricing levers

• Tender pricing at group purchasing organization level
• Channel mix (direct hospital purchase vs distributor)
• Pack size economics (per-dose cost and wastage)
• Substitution elasticity (saline vs dextrose vehicle acceptability)

Container-level levers (plastic vs non-plastic)

• Hospital preference for plastic in certain handling workflows
• Storage, logistics, and compliance requirements
• Compatibility policies that influence which dextrose-based infusion formats are stocked

---

Regulatory and IP posture: what changes the timeline and risk profile?

For a generic formulation like theophylline + dextrose 5%, the binding constraints on timeline usually come from:

• Regulatory file ownership (ANDA/MAA dossiers, reference product linkage)
• Container closure system requirements (plastic container specs and stability data)
• Labeling and concentration equivalence requirements (bioequivalence logic typically not needed for simple IV solutions, but regulatory comparability and stability still matter)

Patent risk A formulation-specific IP analysis requires access to patent families covering:

• theophylline IV infusion concentration (0.08% w/v)
• vehicle/dextrose combination claim scope
• container/packaging claim scope
• manufacturing process claims

No patent family or jurisdiction list is provided in the prompt, so no patent risk and no freedom-to-operate conclusions can be stated.

---

What is the actionable takeaway for R&D and commercialization planning?

Because no formulation-specific clinical trials record, no SKU-level market data, and no patent family coverage is provided, the only actionable business step based on the prompt is to treat this as a generic IV formulation requiring:

• SKU-level identification for any pricing and volume forecast
• regulatory dossier linkage confirmation for availability risk
• market access route mapping through hospital formularies and purchasing tenders

Numerically grounded planning cannot be produced from the supplied prompt alone.

---

Key Takeaways

• This prompt defines a specific IV infusion formulation: theophylline 0.08% + dextrose 5% in plastic.
• A clinical trials update cannot be produced without an attributable formulation-specific trial record set.
• A market analysis and numerical projection cannot be produced without SKU-level baseline sales, geography, and channel/tender data.
• The decision path for this generic IV SKU depends on hospital purchasing dynamics, seasonal acute demand, stock-out risk, and container preference, not on claim differentiation.

FAQs

1. Is there a known clinical trial program for theophylline 0.08% in dextrose 5% (plastic container)?
   The prompt does not provide an attributable trial record set; a formulation-specific trials update cannot be generated.

2. What typically drives hospital demand for IV theophylline products?
   ED and ICU utilization, seasonal respiratory peaks, and local formulary and substitution practices.

3. How do container formats affect commercialization for IV infusions?
   Plastic container preference can reduce handling friction and align with hospital compatibility and storage workflows, influencing stocking decisions.

4. Can pricing be forecast without SKU sales history?
   Not in a defensible way; pricing for hospital generics is heavily shaped by tenders, pack economics, and substitution rules.

5. Does IP meaningfully change timelines for this type of product?
   For generic IV solutions, timeline risk often ties to dossier ownership, packaging-specific regulatory needs, and process claims, but no patent coverage is provided in the prompt.

---

References

[1] No sources were provided in the prompt, and no formulation-specific public trial or regulatory documents were cited.